dr. NSH (Nicolas) Xander, MSc

Erasmus School of Health Policy & Management

PhD candidate | Health Technology Assessment (HTA)

Email: xander@eshpm.eur.nl

Pure profile

Work

Carin A. Uyl-de Groot, Nicolas S.H. Xander, Tom Belleman, Emily A. Burger, Robin Doeswijk, Isabelle Durand-Zaleski, Benjamin P. Geisler, Oliver Groene, Anne Hendrickx, Pia S. Henkel, Renaud Heine, Mirjana Huić, Mauro Melli, Kate Morgan, Monica Racovița, Gauthier Quinonez, Maureen P.M.H. Rutten-van Mölken, Tomáš Tesař, Frederick W. Thielen, Peter Schneider, Yancy S. Wu, Maximilian Salcher-Konrad & Eline Aas (2026) - Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN project - Health Policy and Technology, 15 (2) - doi: 10.1016/j.hlpt.2026.101155 - [link]
Nicolas Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski, Frederick Thielen & Carin Uyl-de Groot (2025) - Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review - The European Journal of Health Economics - doi: 10.1007/s10198-025-01834-y - [link]
N. S.H. Xander, B. Leeneman, A. M.C. Dingemans, W. E. Fiets, W. K. de Jong, N. E.M. Uyl, A. N.M. Wymenga, A. K.L. Reyners & C. A. Uyl-de Groot (2024) - Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? - European Journal of Cancer, 209 - doi: 10.1016/j.ejca.2024.114262 - [link]
Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - European Journal of Cancer, 202 - doi: 10.1016/j.ejca.2024.114002 - [link]
Nicolas S.H. Xander, W. Edward Fiets & Carin A. Uyl-de Groot (2023) - Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands - Frontiers in Oncology, 13 - doi: 10.3389/fonc.2023.1205700 - [link]